Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P08758
UPID:
ANXA5_HUMAN
Alternative names:
Anchorin CII; Annexin V; Annexin-5; Calphobindin I; Endonexin II; Lipocortin V; Placental anticoagulant protein 4; Placental anticoagulant protein I; Thromboplastin inhibitor; Vascular anticoagulant-alpha
Alternative UPACC:
P08758; D3DNW7; Q6FHB3; Q6FI16; Q8WV69; Q9UDH9
Background:
Annexin A5, known by various names such as Annexin V, Placental anticoagulant protein I, and Vascular anticoagulant-alpha, plays a pivotal role in the blood coagulation cascade. It acts as an indirect inhibitor of the thromboplastin-specific complex, showcasing its anticoagulant properties.
Therapeutic significance:
Given its involvement in recurrent pregnancy loss, a condition marked by spontaneous abortion before 24 weeks of gestation, Annexin A5's study is crucial. Understanding the role of Annexin A5 could open doors to potential therapeutic strategies for managing this pregnancy complication.